Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
July 2, 2024 3:04 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,001.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Approval of donanemab (branded Kisunla) is likely to expand revenue for both Lilly and Biogen/Eisai as two players are needed to grow infrastructure.... More
Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'
July 2, 2024 2:41 PM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,023.00 price target on Eli Lilly (NYSE: LLY)
The analyst comments "The approval was in line with our expectations and we expect LLY shares to trade flat to slightly up as a result. For... More
